Table 3.

Clinical Trials of Bevacizumab for Colorectal Cancer

Study	Phase	Number of patients	Presentation	Radiation dose/fractions	Bevacizumab dose	Chemotherapy	Surgery	Pathologic complete response
Czito 2007	I	11 rectal	T3/T4 or N+	50.4 Gy/28	10-15 mg/kg	Capcitabine, oxaliplatin	9 LAR, 2 APR	18%
Willett 2010	I/II	32 rectal	T3/T4	50.4 Gy/28	5-10 mg/kg	5-fluorouracil	8 APR, 24 LAR	16%
Crane 2010	II	25 rectal	T3/T4 or N+	50.4 Gy/28	5 mg/kg	Capcitabine	6 APR, 18 LAR 1 local excision	32%
Velenik 2011	II	61 rectal	T3/T4 or N+	50.4 Gy/28	5 mg/kg	Capecitabine	70% sphincter preserving	13%
Kennecke 2011	II	42 rectal	Partially fixed T3/T4 or N2	50.4 Gy/28	5 mg/kg	Capcitabine, oxaliplatin	19 LAR, 18 APR 1 proctocolectomy	18%
Koukourakis 2009	II	9 rectal 13 colon	Unresectable tumor	67.2 Gy/15*	5 mg/kg	Amifostine, capecitabine	None	NA

Abbreviations: LAR, low anterior resection; APR, abdominoperineal resection; NA, not applicable

^*Biological equivalent dose; conformal hypofractionated (3.4 Gy/fraction × 15) split course accelerated radiation